Cargando…
COMBINING SCLEROSTIN AND DKK1 INHIBITORS TO IMPROVE BONE PROPERTIES IN THE AGED SKELETON
Targeting the secreted Wnt inhibitor sclerostin has been an attractive strategy to improve skeletal health. Sclerostin antibody (romosozumab-aqqg; Evenity) was recently approved by the FDA to treat patients at increased risk of fracture. However, an increased risk of cardiovascular events was report...
Autores principales: | Choi, Roy, Robling, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9766637/ http://dx.doi.org/10.1093/geroni/igac059.2659 |
Ejemplares similares
-
Targeting Sclerostin and Dkk1 at Optimized Proportions of Low-Dose Antibody Achieves Similar Skeletal Benefits to Higher-Dose Sclerostin Targeting in the Mature Adult and Aged Skeleton
por: Choi, Roy B., et al.
Publicado: (2022) -
Role of Wnt-signaling inhibitors DKK-1 and sclerostin in bone fragility associated with Turner syndrome
por: Chiarito, M., et al.
Publicado: (2022) -
Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease
por: Ivanova, Margarita M., et al.
Publicado: (2022) -
A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair
por: Florio, Monica, et al.
Publicado: (2016) -
Co-expression of DKK-1 and Sclerostin in Subchondral Bone of the Proximal Femoral Heads from Osteoarthritic Hips
por: Zarei, Allahdad, et al.
Publicado: (2017)